ASHP DRUG COST MANAGEMENT CONFERENCE WILL "DEVELOP STRATEGIES"
ASHP DRUG COST MANAGEMENT CONFERENCE WILL "DEVELOP STRATEGIES" for dealing with hospital drug budgets that are increasing annually 10%-15% and more, the American Society of Hospital Pharmacists announced Dec. 8 at its midyear clinical meeting in Orlando. Attending the invitational conference will be approximately 50 hospital administrators, split about evenly between CEOs and pharmacy directors. The meeting, to be held in Atlanta Feb. 24-26, will be funded by a $250,000 grant from Hoffmann-La Roche. "If we are going to advance patient care, we cannot ignore the financial issues that affect all our lives," ASHP Executive President Joseph Oddis noted. "At the same time, hospital administrators need to make financial decisions with a clear understanding of how these decisions will affect overall patient care." Speakers scheduled for the upcoming conference include: David Rothman, PhD, the director of Columbia University's Center for the Study of Society and Medicine; Gary Shorb, president of Methodist Hospitals of Memphis; Paul Pierpaoli, the pharmacy director at Rush-Presbyterian-St. Luke's Medical Center; and Alex. Brown pharmaceutical analyst Barbara Ryan. The conference proceedings will be published in ASHP's American Journal of Hospital Pharmacy. ASHP hopes the discussion will contribute to the national health care policy debate. The meeting, entitled "New Approaches to Understanding and Managing the Rising Costs of Pharmaceuticals," will be conducted by the healthcare marketing firm Health Concepts and moderated by the firm's president, Dennis Crimi.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth